Question Bank › Named catch-up gap

Named catch-up gap

Named catch-up gap: management identifies where the company visibly lags peers or its own potential, and is already clos

Calls Tested
500
Answered YES
24
Hit Rate
4.8%
rare by design

Bristol-Myers Squibb Company (BMY) — this company's answers

NO on the Q4 2016 call 2017-01-26 F
The model's full reasoning — Q4 2016 call → NOWe need answer based only on transcript. Need determine if management identifies specific named dimension underperforms relative peers/norms/own potential AND work underway to close gap, meaningful improvement not dependent on market. Need answer YES/NO. Let's parse. The call discusses lung cancer setback, competitive pressure, defending position, etc. Need find management self-diagnosis of specific gap with closing work in motion. Examples? They mention U.S. lung market more competitive due Tecentriq, Keytruda/chemo. They say we know second-line business face increasing competitive pressure, teams focused on defending position. Is that a named gap? They exited at 40% share second-line, gave up 10 points due Tecentriq. But is that "underperforms" relative peers? Possibly. But gap-closing work? "defending our position" not necessarily closing gap. They assume approval of Keytruda/chemo, expect Opdivo flat. That's not a gap they own? Also they mention in RCC regained market share during Q4. That is a gap closed? Let's examine. Question: "Does management IDENTIFY A SPECIFIC, NAMED DIMENSION ON WHICH THE COMPANY CURRENTLY UNDERPERFORMS — relative to industry peers, industry norms, or the company's own demonstrated potential elsewhere in its business — AND describe work ALREADY UNDERWAY to close that specific gap, with management treating the closing of it as a meaningful source of improvement that does not depend on market conditions getting better?" Need answer YES only if management's own words convey one coherent self-diagnosis with both halves. We need identify any specific gap. The call includes "our U.S. lung market has started to become more competitive, mainly due to entry of Tecentriq in second-line." "we did see demand growth, although at a slowing rate." "We know our second-line business will face increasing competitive pressure in 2017, and our teams are focused on defending our position." "we expect Opdivo will be roughly flat with potential to show growth, and we will focus on defending our second-line position and driving adoption in other indications." That is not "underperforms" but market share erosion. Also "In the U.S., we did see demand growth, although at a slowing rate.

← Back to the full BMY analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management IDENTIFY A SPECIFIC, NAMED DIMENSION ON WHICH THE COMPANY CURRENTLY UNDERPERFORMS — relative to industry peers, industry norms, or the company's own demonstrated potential elsewhere in its business — AND describe work ALREADY UNDERWAY to close that specific gap, with management treating the closing of it as a meaningful source of improvement that does not depend on market conditions getting better? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent self-diagnosis with both halves present: (1) A NAMED GAP, OWNED BY MANAGEMENT: management itself states, concretely, where the company lags — for example margins, productivity, utilization, pricing, mix, service levels, penetration of its own customer base, or performance of one region, segment, or facility versus the company's own better ones or versus what peers demonstrably achieve — identified specifically enough that a reader knows exactly what is deficient and roughly how large the shortfall is; and (2) CLOSING WORK IN MOTION WITH THE MECHANISM EXPLAINED: management describes the concrete actions already executing to close it — not aspirations — and conveys why the gap is closable by the company's own effort (the better level is already achieved by peers or by the company's own best operations, so the target is demonstrated rather than theoretical), with early progress or a credible operational path visible in the current period. Answer NO if management only claims general improvement opportunity without naming a specific measurable gap. NO if the gap is blamed on external conditions that must improve. NO if the closing work is only planned, promised, or under study. NO if the gap-closing is ordinary cost-cutting rhetoric with no named benchmark. NO if the diagnosis appears only in an analyst's question that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
MEG Montrose Environmental Group, Inc. Q3 2023 2023-11-08 C+
RVLV Revolve Group, Inc. Q3 2023 2023-11-01 C
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
SWK Stanley Black & Decker, Inc. Q1 2023 2023-05-04 D
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
KD Kyndryl Holdings, Inc. Q4 2021 2022-03-01 C+
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
LPTH LightPath Technologies, Inc. Q4 2021 2021-09-09 D
KOP Koppers Holdings Inc. Q2 2018 2018-08-12 C+
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
ADNT Adient plc Q1 2018 2018-01-29 D
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
STKL SunOpta Inc. Q2 2017 2017-08-09 C+
PTC PTC Inc. Q3 2017 2017-07-19 C+
ABM ABM Industries Incorporated Q2 2017 2017-06-08 B
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C
PDCO Patterson Companies, Inc. Q3 2017 2017-02-23 C
SXT Sensient Technologies Corporation Q4 2016 2017-02-10 A
BC Brunswick Corporation Q3 2016 2016-10-28 B+
SON Sonoco Products Company Q4 2015 2016-02-11 B

How the model reasoned

HOLX · Q4 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly diagnosing Cynosure’s commercial organization as the specific underperforming dimension (salesforce turnover, recruiting, and productivity lagging behind the company’s international business and its own best operations). They then describe concrete, already-executing actions—stopping voluntary turnover, rehiring high performers, instituting 90-day reviews, new compensation, and building “Cynosure 2.0”—as the mechanism to close the gap.
STKL · Q2 2017 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management identifying a specific named gap in the bars segment, where operational issues at a particular facility are causing inefficient production and gross margin losses. They describe a rapid recovery team already executing systematic identification and correction of these issues, treating the gap as closable through their own operational efforts rather than external market improvements — this aligns with the criteria for a meaningful source of improvement.
ADNT · Q1 2018 → YESThe question is: Does management identify a specific, named dimension on which the company currently underperforms — relative to industry peers, industry norms, or the company's own demonstrated poten...YES The transcript shows management explicitly naming the Seat Structures and Mechanisms (SS&M) business as the specific underperforming dimension. They state it is “destroyed shareholder value” when run as currently organized, and that it is “impacting our financial results” with “significant impact.

More from the question bank

Paid to expand: the company's growth spendinThe product is disappearing into reorder rhyRecently unlocked doorWorking for customers it could not have servVolume records through a still-fixed gateTwo-sided intensityAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.